Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). ...

Trulicity has been stealing market share from Novo’s older daily GLP-1, Victoza (liraglutide), but Novo hopes that strong trial data built up during clinical development will be enough to ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Groups G and H used pure GLP-1 drugs (semaglutide and liraglutide ... as injected liraglutide and noted that Victoza had annual sales of $1.656 billion as of April, 2024.

liraglutide is approved as Victoza for diabetes and Saxenda for obesity. And understanding the risks in adolescents, whose use of GLP-1 drugs has soared since they were approved for the age group ...